BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 19709071)

  • 21. [Recurrence following radical surgery for prostatic cancer. Analysis of clinical, biological and anatomo-pathological prognostic factors].
    Feyaerts A; Delrée A; Lorge F; Opsomer RJ; Wese FX; Van Cangh PJ; Draguet AP; Cosyns JP
    Acta Urol Belg; 1997 Mar; 65(1):11-8. PubMed ID: 9245198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
    Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S
    BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radical retropubic prostatectomy in men younger than 45 years diagnosed during early prostate cancer detection program.
    Varkarakis J; Pinggera GM; Sebe P; Berger A; Bartsch G; Horninger W
    Urology; 2004 Feb; 63(2):337-41. PubMed ID: 14972485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
    Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M
    BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
    Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
    Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Altered prostate specific antigen reference range after transurethral resection of the prostate.
    Wolff JM; Boekels O; Borchers H; Jakse G; Rohde D
    Anticancer Res; 2000; 20(6D):4977-80. PubMed ID: 11326651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are repeat biopsies required in men with PSA levels < or =4 ng/ml? A Multiinstitutional Prospective European Study.
    Djavan B; Fong YK; Ravery V; Remzi M; Horninger W; Susani M; Kreuzer S; Boccon-Gibod L; Bartsch G; Marberger M
    Eur Urol; 2005 Jan; 47(1):38-44; discussion 44. PubMed ID: 15582247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical relevance of transurethral resection of the prostate in "asymptomatic" patients with an elevated prostate-specific antigen level.
    van Renterghem K; Van Koeveringe G; Achten R; Van Kerrebroeck P
    Eur Urol; 2007 Sep; 52(3):819-26. PubMed ID: 17418482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 'Vanishing' prostate cancer in radical prostatectomy specimens: incidence and long-term follow-up in 38 cases.
    Bostwick DG; Bostwick KC
    BJU Int; 2004 Jul; 94(1):57-8. PubMed ID: 15217431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases.
    Osunkoya AO; Nielsen ME; Epstein JI
    Am J Surg Pathol; 2008 Mar; 32(3):468-72. PubMed ID: 18300802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diffuse adenosis of the peripheral zone in prostate needle biopsy and prostatectomy specimens.
    Lotan TL; Epstein JI
    Am J Surg Pathol; 2008 Sep; 32(9):1360-6. PubMed ID: 18670353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
    Bhatta-Dhar N; Reuther AM; Zippe C; Klein EA
    Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The maximum tumour length in biopsy cores as a predictor of outcome after radical prostatectomy.
    Hayashi N; Urashima M; Kuruma H; Arai Y; Kuwao S; Iwamura M; Egawa S
    BJU Int; 2008 Jan; 101(2):175-80. PubMed ID: 17850362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.